This session will examine first-line treatment strategies for HER2-positive gastroesophageal cancer, comparing established HER2-targeted regimens with emerging next-generation combinations. Faculty will review key clinical data, biomarker considerations, and mechanisms of resistance, while discussing practical factors that influence treatment selection and sequencing. Participants will gain insight into optimizing care in a rapidly evolving landscape. This discussion will highlight established HER2-targeted regimens as the foundation of first-line treatment. Faculty will review pivotal data supporting chemotherapy plus trastuzumab-based approaches, with or without immunotherapy, focusing on survival outcomes, safety, and broad clinical applicability. Practical guidance on patient selection and toxicity management will be emphasized.

This session will examine first-line treatment strategies for HER2-positive gastroesophageal cancer, comparing established HER2-targeted regimens with emerging next-generation combinations. Faculty will review key clinical data, biomarker considerations, and mechanisms of resistance, while discussing practical factors that influence treatment selection and sequencing. Participants will gain insight into optimizing care in a rapidly evolving landscape. This discussion will explore next-generation HER2-directed combinations in the first-line setting. Faculty will review emerging data on novel agents and combination strategies, focusing on improving response depth and durability. Key considerations include biologic rationale, resistance mechanisms, toxicity, and integration into clinical practice.

This debate will examine the evolving role of oral selective estrogen receptor degraders (SERDs) in breast cancer and address the question of whether these agents are truly interchangeable. Compare differences in mechanism of action, clinical efficacy, resistance profiles, and safety across available and emerging oral SERDs. Speakers will highlight implications for patient selection and sequencing in hormone receptor-positive disease and provide expert insight into how nuanced differences among oral SERDs may influence real-world treatment decisions. Faculty will review shared mechanisms of action, class-wide efficacy data, and common safety profiles across available, largely comparable therapeutic agents. The discussion will address whether differences among oral SERDs translate into meaningful distinctions in clinical practice, and participants will gain insight into the rationale for viewing oral SERDs as a broadly similar therapeutic class in hormone receptor-positive breast cancer.

This debate will examine the evolving role of oral selective estrogen receptor degraders (SERDs) in breast cancer and address the question of whether these agents are truly interchangeable. Compare differences in mechanism of action, clinical efficacy, resistance profiles, and safety across available and emerging oral SERDs. Speakers will highlight implications for patient selection and sequencing in hormone receptor-positive disease and provide expert insight into how nuanced differences among oral SERDs may influence real-world treatment decisions. Our presenters will examine differences in pharmacology, potency, resistance profiles, and clinical trial outcomes among available and emerging agents, discussing how these distinctions may influence patient selection, sequencing, and combination strategies. Delve into the clinical relevance for patients of heterogeneity within the oral SERD class.

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care. The speaker will review clinical trial data supporting preoperative systemic approaches, including chemotherapy and immunotherapy, and their impact on pathologic response and surgical outcomes. The discussion will address patient selection, timing of surgery, and safety considerations, and revisit the benefits and limitations of neoadjuvant strategies in resectable lung cancer.

Faculty will examine treatment strategies for patients with resectable lung cancer and discuss whether a neoadjuvant-only strategy is sufficient for disease control or if incorporating both neoadjuvant and adjuvant therapy through a perioperative approach offers greater benefit. Discussion will review emerging clinical trial data, survival outcomes, and toxicity considerations. Participants will explore how these approaches may be optimally applied in contemporary resectable lung cancer care. Examine perioperative therapy strategies for patients with resectable lung cancer, incorporating both neoadjuvant and adjuvant treatment approaches. Faculty will review evidence demonstrating how perioperative systemic therapy may improve recurrence risk and long-term survival outcomes, while addressing sequencing considerations, toxicity management, and coordination of care across the surgical and medical oncology settings.

Faculty will critically evaluate current evidence, including trial data, biomarkers, and patient selection considerations, to clarify where immunotherapy offers meaningful benefit and where uncertainty remains in the treatment of triple-negative breast cancer. Presenters will provide expert insight into translating evolving data into real-world clinical decision-making. Through this balanced discussion, participants will gain a nuanced understanding of the risks, benefits, and limitations of universal versus selective use of immune checkpoint inhibitors in TNBC. Explore the rationale and evidence behind the use of immune checkpoint inhibitor therapy in patients with TNBC. Discussion will review key clinical trial data, mechanisms of action, and the role of biomarkers in guiding treatment decisions. Faculty will also address ongoing controversies, including patient selection, toxicity considerations, and real-world applicability. Participants will gain a clearer understanding of the potential benefits and limitations of broadly applying immunotherapy across the TNBC population.

Faculty will critically evaluate current evidence, including trial data, biomarkers, and patient selection considerations, to clarify where immunotherapy offers meaningful benefit and where uncertainty remains in the treatment of triple-negative breast cancer. Presenters will provide expert insight into translating evolving data into real-world clinical decision-making. Through this balanced discussion, participants will gain a nuanced understanding of the risks, benefits, and limitations of universal versus selective use of immune checkpoint inhibitors in TNBC. Examine the evidence supporting a selective approach to the use of immune checkpoint inhibitor therapy in patients with TNBC. Faculty will review clinical trial data, biomarker-driven strategies, and patient-specific factors that influence treatment benefit and risk. The discussion will address toxicity, cost, and limitations of current evidence in certain TNBC subgroups, as well as how to individualize immunotherapy decisions to optimize outcomes while minimizing unnecessary treatment.

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy. Faculty will examine available evidence on recurrence risk reduction, survival outcomes, and toxicity profiles associated with each approach. The discussion will address practical considerations influencing treatment choice and provide new insight into whether adjuvant HAI offers added benefit over standard systemic chemotherapy. Adjuvant HAI therapy has a meaningful role following liver resection compared with adjuvant systemic chemotherapy alone. Faculty will review clinical evidence demonstrating improved hepatic disease control and survival outcomes with HAI in selected patients, guiding learners through scenarios in which adjuvant HAI may optimize outcomes.

Explore postoperative treatment strategies following liver resection, comparing the role of adjuvant hepatic arterial infusion (HAI) therapy with systemic adjuvant chemotherapy. Faculty will examine available evidence on recurrence risk reduction, survival outcomes, and toxicity profiles associated with each approach. The discussion will address practical considerations influencing treatment choice and provide new insight into whether adjuvant HAI offers added benefit over standard systemic chemotherapy. Faculty will review limitations of the available evidence for adjuvant HAI therapy after liver resection, including lack of randomized data, toxicity concerns, and challenges related to access and expertise. This discussion will address whether modern systemic therapies can provide comparable benefit without the added complexity of HAI.

In this debate, faculty will examine clinical trial evidence, efficacy across risk groups, toxicity profiles, and sequencing considerations that inform first-line treatment selection in metastatic renal cancer. The discussion will highlight ongoing controversies regarding durability of response versus disease control. Providers will share expert insights on applying these strategies in real-world practice. Review pivotal clinical trial data, response durability, and survival outcomes associated with dual immunotherapy regimens, and learn approaches to patient selection, toxicity management, and predictors of long-term benefit. Participants will gain insight into the role of doublet immune checkpoint blockade in contemporary metastatic renal cancer care.

In this debate, faculty will examine clinical trial evidence, efficacy across risk groups, toxicity profiles, and sequencing considerations that inform first-line treatment selection in metastatic renal cancer. The discussion will highlight ongoing controversies regarding durability of response versus disease control. Providers will share expert insights on applying these strategies in real-world practice. Discussion of key clinical trial data will demonstrate improvements in response rates and progression-free survival with combination approaches. Faculty will address toxicity profiles, patient selection, and practical considerations for managing combination therapy in routine practice, and expand participants’ knowledge of the role of immune checkpoint inhibitors plus VEGFR TKI regimens in the evolving treatment landscape of metastatic renal cancer.

Faculty will contrast monotherapy approaches with emerging combination strategies in the optimal first-line treatment of NSCLC and examine whether combining targeted agents with additional modalities improves long-term outcomes. The discussion will highlight efficacy, toxicity, resistance patterns, and sequencing considerations across available approaches. Presenters will provide expert perspective on integrating evolving clinical evidence into real-world treatment decisions.

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate. This session will focus on safety considerations surrounding IO rechallenge, covering the incidence and management of recurrent or cumulative immune-related adverse events associated with reinitiation of IO therapy. The discussion will address risk factors, monitoring strategies, and clinical scenarios where rechallenge may pose significant concern, giving participants insight into balancing patient safety with potential therapeutic benefit when considering IO rechallenge.

Explore the role of immunotherapy (IO) rechallenge in the management of esophageal and gastric cancers, weighing safety concerns against the potential clinical benefit of reinitiation. Speakers will review evidence on efficacy, patterns of response, and the risk of recurrent or cumulative immune-related adverse events, and address clinical scenarios in which IO rechallenge may be appropriate. Faculty will review emerging clinical evidence and real-world data suggesting renewed antitumor activity in select patients following reinitiation of IO therapy. Discussion will address factors associated with response, optimal timing, and patient selection. Participants will gain perspective on scenarios in which IO rechallenge may offer meaningful clinical benefit despite prior treatment exposure.

This debate will examine the role of circulating tumor DNA (ctDNA) testing in the adjuvant management of early-stage breast cancer outside of clinical trials. Faculty will explore the potential clinical value of ctDNA for detecting minimal residual disease, guiding treatment escalation or de-escalation and informing prognosis. The discussion will also address limitations of current evidence, assay variability, and ethical and practical considerations. Session presenters will give their expert perspective on whether and how ctDNA testing should be integrated into routine adjuvant care. Faculty will review emerging data supporting ctDNA as a tool for detecting minimal residual disease and identifying patients at higher risk for recurrence, addressing how ctDNA results may inform earlier intervention, treatment intensification, or closer surveillance. Participants will gain insight into the potential clinical utility of ctDNA testing in real-world adjuvant breast cancer care.

This debate will examine the role of circulating tumor DNA (ctDNA) testing in the adjuvant management of early-stage breast cancer outside of clinical trials. Faculty will explore the potential clinical value of ctDNA for detecting minimal residual disease, guiding treatment escalation or de-escalation and informing prognosis. The discussion will also address limitations of current evidence, assay variability, and ethical and practical considerations. Session presenters will give their expert perspective on whether and how ctDNA testing should be integrated into routine adjuvant care. Current limitations in evidence, including uncertainty around clinical actionability, impact on outcomes, and optimal management of positive results, define the conversation around the use of ctDNA in cancer therapy. This discussion will address concerns related to assay variability, false positives, cost, and patient anxiety, and explore why ctDNA testing may be best reserved for investigational settings until prospective data clarify its role.

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care. Review evidence supporting continued systemic treatment for cancer control, including outcomes with targeted therapy, immunotherapy, and combination regimens. The speaker will address durability of response and scenarios in which local interventions may be deferred. Participants will gain insight into optimizing systemic therapy strategies for patients with limited residual metastatic disease.

Faculty will examine whether systemic therapy alone is sufficient for control of oligo-remnant lung cancer, or if the addition of local ablation improves progression-free survival and long-term outcomes. The discussion will review patient selection, timing of intervention, and available local treatment modalities. Speakers will discuss their experience with integrating systemic and local approaches in contemporary lung cancer care. Explore the use of systemic therapy combined with local ablative approaches in the management of oligo-remnant metastatic lung cancer by reviewing clinical evidence supporting the addition of local treatments, such as stereotactic body radiation therapy or surgical ablation, to improve disease control. Discussion will address integration with ongoing systemic therapy, and cover multimodal strategies for enhancing long-term outcomes in these patients.

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application. This session will cover emerging clinical trial data demonstrating meaningful activity of KRAS- and RAS-targeted agents in biomarker-selected populations. The speaker will address advances in drug development, safety profiles, and integration with existing chemotherapy backbones. Participants will gain insight into how RAS inhibitors may be incorporated into routine management of pancreatic cancer.

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application. Modest efficacy signals, narrow biomarker applicability, and emerging resistance mechanisms represent real concerns in the discussion of RAS inhibitor use in pancreatic cancer. Faculty will discuss safety concerns, durability of response, and unanswered questions regarding optimal sequencing and combinations to inform learners on why RAS inhibitors remain best positioned within clinical trials rather than routine practice at this time.

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as mirvetuximab with traditional platinum-based sequencing strategies, reviewing clinical evidence, resistance patterns, and practical considerations. Participants will gain insight into how emerging therapies may reshape decision-making. This discussion will focus on the growing role of ADCs, including mirvetuximab, as biomarker-selected therapies. Faculty will review clinical trial data supporting improved outcomes in target-expressing populations and discuss how biomarker testing can guide treatment selection, improve precision, and potentially shift sequencing paradigms.

This session will examine treatment selection in recurrent ovarian cancer in the era of antibody-drug conjugates (ADCs). Faculty will compare biomarker-driven use of agents such as mirvetuximab with traditional platinum-based sequencing strategies, reviewing clinical evidence, resistance patterns, and practical considerations. Participants will gain insight into how emerging therapies may reshape decision-making. This discussion will emphasize the continued importance of platinum sensitivity in guiding treatment sequencing. Faculty will review evidence supporting established platinum-based approaches and argue that clinical context and sequencing strategy remain more impactful than target expression alone, with attention to durability, toxicity, and real-world applicability.

Explore the optimization of immunotherapy in muscle-invasive bladder cancer by examining emerging clinical trial data, pathologic response rates, and survival outcomes associated with each strategy. Discussion will address patient selection, timing of immunotherapy, and integration with surgery and systemic treatment. Speakers will provide expert perspectives on applying these evolving strategies in clinical practice. This session will focus on the benefits of neoadjuvant IO-containing systemic therapy in patients with muscle-invasive bladder cancer. Faculty will review clinical trial data demonstrating pathologic response rates, early survival signals, and potential downstaging benefits prior to cystectomy. Participants will learn how neoadjuvant IO-based approaches may improve outcomes.

Explore the optimization of immunotherapy in muscle-invasive bladder cancer by examining emerging clinical trial data, pathologic response rates, and survival outcomes associated with each strategy. Discussion will address patient selection, timing of immunotherapy, and integration with surgery and systemic treatment. Speakers will provide expert perspectives on applying these evolving strategies in clinical practice. Examine the benefits of risk-adapted adjuvant IO therapy in patients with muscle-invasive bladder cancer. Faculty will review evidence supporting adjuvant IO for patients at high risk of recurrence following definitive local therapy, addressing biomarker and pathologic features used to guide risk stratification, as well as safety and duration of therapy. Explore how tailoring adjuvant immunotherapy based on individual risk can optimize outcomes in muscle-invasive bladder cancer.

This session will explore first-line treatment strategies for advanced or recurrent endometrial cancer, examining whether chemo-immunotherapy should be broadly applied or tailored based on molecular subtype. Faculty will review key clinical trial data, including outcomes by mismatch repair status, and discuss biomarker-driven decision-making, toxicity considerations, and real-world implementation. Participants will gain practical insight into optimizing treatment selection in a rapidly evolving landscape. This discussion will support chemo-immunotherapy as a new standard across patient populations. Faculty will highlight pivotal trials demonstrating improved outcomes with the addition of immunotherapy to chemotherapy, regardless of mismatch repair status, and discuss durability of benefit, safety, and ease of implementation in routine practice.

This session will explore first-line treatment strategies for advanced or recurrent endometrial cancer, examining whether chemo-immunotherapy should be broadly applied or tailored based on molecular subtype. Faculty will review key clinical trial data, including outcomes by mismatch repair status, and discuss biomarker-driven decision-making, toxicity considerations, and real-world implementation. Participants will gain practical insight into optimizing treatment selection in a rapidly evolving landscape. This discussion will argue for a more tailored approach in pMMR/MSS disease. Faculty will examine the comparatively modest benefit of immunotherapy in this subgroup and emphasize the role of targeted combinations and molecular subtyping to guide treatment. Practical considerations around patient selection, sequencing, and emerging data will be addressed.

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting. This session will focus on the role of continuing standard cytotoxic therapy for patients with lung cancer who experience disease progression after frontline chemoimmunotherapy. Faculty will review evidence supporting commonly used second-line chemotherapy options, including expected efficacy and toxicity profiles. Learners will gain perspective on when traditional cytotoxic approaches remain an appropriate and effective strategy after chemoimmunotherapy failure.

Faculty will explore management strategies for patients with lung cancer following progression on frontline chemoimmunotherapy, examining available evidence supporting second-line chemotherapy options alongside novel strategies such as targeted agents, antibody-drug conjugates, and clinical trial enrollment. The discussion will address toxicity considerations and goals of care in the post-progression setting. Examine strategies for transitioning to alternative approaches beyond standard cytotoxic therapy in patients with progressive lung cancer. Speakers will review emerging treatment options, including targeted therapies, antibody-drug conjugates, novel immunotherapy strategies, and clinical trial opportunities. The discussion will address biomarker-driven decision-making, safety considerations, and patient selection, giving participants insight into how innovative therapeutic approaches may improve outcomes after chemoimmunotherapy failure.

This debate will examine the optimal timing of lutetium-PSMA therapy in the management of metastatic prostate cancer with a review of clinical trial evidence, patient selection criteria, and outcomes associated with different sequencing strategies. The discussion will address potential benefits of earlier intervention versus reserving lutetium-PSMA for more advanced disease stages. Our presenters will provide expert insight into how timing considerations may influence treatment outcomes in metastatic prostate cancer. Review emerging clinical trial data supporting earlier integration of PSMA-targeted radioligand therapy and its potential impact on disease control and survival outcomes, including discussion of patient selection, sequencing with existing systemic therapies, and safety considerations. Explore the rationale and challenges of moving lutetium-PSMA earlier in the treatment paradigm.

This debate will examine the optimal timing of lutetium-PSMA therapy in the management of metastatic prostate cancer with a review of clinical trial evidence, patient selection criteria, and outcomes associated with different sequencing strategies. The discussion will address potential benefits of earlier intervention versus reserving lutetium-PSMA for more advanced disease stages. Our presenters will provide expert insight into how timing considerations may influence treatment outcomes in metastatic prostate cancer. Faculty will provide an overview of evidence supporting the use of lutetium-PSMA after progression on standard systemic therapies, including androgen receptor-targeted agents and chemotherapy. Discussion will address expected efficacy and management of treatment-related toxicities in heavily pretreated populations, leading participants to new perspective on how lutetium-PSMA fits into established sequencing strategies.